Presentation deck for Building a cell therapy franchise: SURPASS Phase 1 trial data at ESMO September 13, 2021

Ad Rawcliffe, CEO, and Elliot Norry, CMO

Building a cell therapy franchise: SURPASS Phase 1 trial data at ESMO September 13, 2021

Disclaimer

This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 9, 2021 and our other SEC filings.

We urge you to consider these factors carefully in evaluating the forward-looking statements herein and you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this presentation speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

2

Our vision and mission

Arming Cells.

Against Cancer.

For Good.

To transform the lives of people with cancer by designing and delivering cell therapies

3

5-year core value drivers: our "2-2-5-2" plan

TwoTwoFive

marketed	additional BLAs	autologous
SPEAR T-cell	for SPEAR T-cell	products in the
products targeting	products	clinic
MAGE-A4
•	Synovial sarcoma	•	Additional indications	•	HiT
•	Esophageal and		for MAGE-A4	•	Next-gen TILs
	targeted products
	EGJ cancers		•	New targets
		•	ADP-A2AFP
		•	Broader HLA

coverage

Two

allogeneic products entering the clinic

• SPEAR T-cell product targeting MAGE-A4
• HiT mesothelin - partnered with Astellas

Integrated Cell Therapy Capabilities

Research | Preclinical | Translational | Clinical | CMC | Regulatory | Commercial

4 EGJ: esophagogastric junction cancer; HiT: HLA-independentT-cell receptor (TCR); TIL: tumor infiltrating lymphocyte; CMC: chemistry, manufacturing, and controls

SURPASS is a signal finding trial with our next-generation SPEAR T-cells targeting MAGE-A4

Two

marketed SPEAR T-cell products targeting MAGE-A4

• Synovial sarcoma
• Esophageal and EGJ cancers

Two

additional BLAs for SPEAR T-cell products

• Additional indications for MAGE-A4 targeted products
• ADP-A2AFP

SURPASS Trial BOR in 6 patients with

multiple tumor indications

2	Data cut-off October 1, 2020

2

2

Decision to focus on lung, head and neck, bladder, and gastroesophageal cancers

5 EGJ: esophagogastric junction cancer; MRCLS: myxoid/round cell liposarcoma; H&N: head and neck cancer indicates gastroesophageal tumor indications